Clinical trials: Pancreatic Tumor
Gastrointestinal Cancer
Validating M.D. Anderson Symptom Inventory (MDASI-GI) in GI Cancer Patients Under Chemotherapy
The goal of this study is to learn more about the symptoms that may occur in patients with GI cancer. The types of GI cancer being studied are cancers of the stomach, liver, pancreas, colon, and rectum.
- Trial name
- NCT00849979
- Testing
- Questionnaire, Interview
- Where
- United States
- Volunteers
- 184 people
- Sponsor
- M.D. Anderson Cancer Center
Pancreatic Cancer Pain, Intrathecal Analgesic
Evaluating the Effectiveness of AIT in the Treatment of Pain Related to Pancreatic Cancer
The aim of this clinical trial is to assess the effectiveness of intratracheal analgesia on pain intensity in cancer patients, from the start of treatment up to 3 months. It will also investigate the safety of this technique.
- Conditions
- Pancreatic Cancer Pain, Intrathecal Analgesic, Intrathecal Administration of the Drug, Pancreatic Carcinoma
- Trial name
- PIT (NCT07733427)
- Testing
- Intrathecal catheter connected to an implantable pump, Administration of medication, including analgesics, via an intrathecal catheter connected to an implantable pump or via periodic injections
- Where
- 3 sites in France
- Volunteers
- 40 people
- Sponsor
- Clinique Bizet
Chemotherapeutic Agent Toxicity, Pancreatic Cancer
Chemotherapy With or Without Dalteparin in Treating Patients With Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Chemotherapeutic Agent Toxicity, Pancreatic Cancer, Thromboembolism
- Trial name
- PAM07 (NCT00662688)
- Testing
- daltéparine, Chemotherapy at the investigator's discretion
- Where
- 6 sites in France
- Volunteers
- 42 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Metastatic Pancreatic Cancer, Nonresectable Pancreatic Cancer
A Phase II Trial of CG 8020 and CG 2505 in Patients With Nonresectable or Metastatic Pancreatic Cancer
To evaluate the safety and effectiveness of CG8020 and CG2505.
- Trial name
- NCT00245362
- Testing
- CG 8020 and CG 2505
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Cell Genesys
Pancreatic Cancer, Obstructive Jaundice
A New Strategy for Preoperative Drainage of Resectable Pancreatic Head Cancer Combined Severe Obstructive Jaundice
Severe obstructive jaundice caused by pancreatic head cancer usually requires preoperative biliary drainage, but its necessity and effectiveness are controversial, and specific strategies lack clear standards.
- Trial name
- PROB (NCT06541340)
- Testing
- Modified strategy, Traditional strategy
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Ruijin Hospital
Metastatic Malignant Neoplasm in the Brain, Metastatic Solid Neoplasm
APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of APN401 in treating patients with pancreatic cancer, colorectal cancer, or other solid tumors that have spread to other places in the body or have come back.
- Conditions
- Metastatic Malignant Neoplasm in the Brain, Metastatic Solid Neoplasm, Recurrent Colorectal Carcinoma, Recurrent Pancreatic Carcinoma
- Trial name
- NCT03087591
- Testing
- Laboratory Biomarker Analysis, siRNA-transfected Peripheral Blood Mononuclear Cells (PBMC) APN401
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Wake Forest University Health Sciences
Breast Cancer Metastatic, Pancreatic Carcinoma Metastatic
Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors
Primary Objective: For Cohort A, Cohort B, and Cohort C Part 2: To assess the antitumor activity of tusamitamab ravtansine in metastatic breast cancer (mBC) and tusamitamab ravtansine monotherapy and in combination with…
- Trial name
- CARMEN-BT01 (NCT04659603)
- Testing
- tusamitamab ravtansine, Gemcitabine
- Where
- 29 sites in United States, Argentina and 8 more
- Volunteers
- 50 people
- Sponsor
- Sanofi
Neuroendocrine Tumors
Nonfunctioning Small (≤2 cm) Neuroendocrine Pancreatic Incidentaloma
Neuroendocrine tumors (NETs) and carcinomas account for 10-15 % of all pancreatic incidentalomas. The management of pancreatic NETs depends on tumor stage and on presence or not of hormonal syndrome.
- Trial name
- NCT03022188
- Where
- 22 sites in Belgium, France
- Volunteers
- 100 people
- Sponsor
- Société Française d'Endoscopie Digestive
Breast Diseases, Polycystic Ovary
Breast Ultrasonography and Polycystic Ovary Syndrome
The results of the evaluation of breast ultrasonography results of patients with polycystic ovary syndrome diagnosis over 30 years of age will be evaluated.
- Trial name
- NCT04231786
- Testing
- Breast ultrasonography findings
- Where
- Turkey (Türkiye)
- Volunteers
- 1 people
- Sponsor
- Kanuni Sultan Suleyman Training and Research Hospital
Pancreatic Cancer, Cholangiocarcinoma
Oral Protein Supplements for Nutritional and Quality of Life Improvement After Pancreatic Resection in Elderly Patients
This study investigates the effects of oral protein supplements on the nutritional status and quality of life in elderly patients following standard pancreatic resection.
- Conditions
- Pancreatic Cancer, Cholangiocarcinoma, Intraductal Papillary Mucinous Neoplasm, Neuroendocrine Tumor
- Trial name
- NCT06570174
- Testing
- oral protein supplements
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Yonsei University
Pancreatic Neuroendocrine Tumors (pNET)
Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors
This was a multicenter, open label, randomized phase II study to evaluate the efficacy and safety of BEZ235 as compared to everolimus in patients with advanced, low to intermediate grade pancreatic neuroendocrine tumor (pNET).
- Trial name
- NCT01628913
- Testing
- BEZ235, Everolimus
- Where
- 26 sites in United States, France and 6 more
- Volunteers
- 62 people
- Sponsor
- Novartis Pharmaceuticals
Pancreatic Cancer
XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer
This trial will include 2 portions (phase 1 and phase 2). The first portion will be a Phase I, open label, dose escalation study to establish the maximum tolerated dose (MTD) of XB2001 as measured by Dose-Limiting Toxicity (DLT)…
- Trial name
- 1-BETTER (NCT04825288)
- Testing
- Phase I: XB2001 250 mg, Phase I: XB2001 500 mg, Phase I: XB2001 1000 mg
- Where
- 30 sites in United States
- Volunteers
- 76 people
- Sponsor
- XBiotech, Inc.
Gynecologic Cancer, Colorectal Cancer
Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs
Long-Term Follow-Up Study for Subjects Enrolled in the Phase I/II Study of Autologous T Cells Engineered using the Sleeping Beauty System to Express T cell Receptors (TCRs) Reactive Against Cancer-specific Mutations in Subjects…
- Conditions
- Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT05292859
- Testing
- Neoantigen specific TCR-T cell drug product
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Alaunos Therapeutics
Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms
CD318-targeted CAR-T Cell Therapy in Patients With Pancreatic Cancer (ResCPa)
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, with limited therapeutic options and a five-year survival rate below 10 % in advanced stages.
- Trial name
- ResCPa (NCT07153289)
- Testing
- CD318-CAR-T cells
- Volunteers
- 38 people
- Sponsor
- University Hospital Tuebingen
Breast Cancer, Liver Cancer
Theranostic Approach by Early Multigene Sequencing in Advanced Poor Prognosis Cancers
The European Society for Medical Oncology (ESMO) strongly recommends to develop multigene sequencing in the framework of molecular screening programmes, in order to improve access to innovative drugs and to accelerate clinical…
- Conditions
- Breast Cancer, Liver Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- ESCAT (NCT06958224)
- Testing
- Large and early multigene sequencing
- Where
- France
- Volunteers
- 360 people
- Sponsor
- University Hospital, Lille
Pancreatic Cancer
Individualized Drug Treatment for Treating Patients With Pancreatic Cancer
RATIONALE: Treating tumor tissue in the laboratory with different drugs may help doctors find the best drug for treating individual patients with pancreatic cancer.
- Trial name
- NCT00276744
- Testing
- cetuximab, capecitabine, docetaxel
- Where
- United States
- Volunteers
- 249 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pancreas Adenocarcinoma, Pancreas Cancer
PACAREG: a Multicenter Registry Trial in Pancreatic Ductal Adencarcinoma
PaCaReg is a multicenter registry trial aiming in the assessement of clinical, epidemiological and biological profiles in patients with pancreatic ductal adenocarcinoma
- Trial name
- PaCaReg (NCT04099134)
- Where
- Germany
- Volunteers
- 5,000 people
- Sponsor
- University of Ulm
Lymphoma, Nasopharyngeal Cancer
Applying PET/MR in Oncology - a Prospective Project
Cancer is a global health issue. According to the World Health Organization, Cancer is the second leading cause of death globally, and is responsible for an estimated 9.6 million deaths in 2018.
- Conditions
- Lymphoma, Nasopharyngeal Cancer, Esophageal Cancer, Cervical Cancer
- Trial name
- NCT04158414
- Testing
- PET/MR scan
- Volunteers
- 500 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
This phase I trial is studying the side effects and best dose of erlotinib hydrochloride when given together with cetuximab and to see how well they work in treating patients with advanced gastrointestinal cancer, head and neck…
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
- Trial name
- NCT00397384
- Testing
- cetuximab, erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Ductal Adenocarcinoma
Investigating Targetable Metabolic Pathways Sustaining Pancreatic Cancer
This clinical trial investigates the nutrients pancreatic cancers depend on in which to survive and the processes these tumors use (metabolism) to obtain these nutrients.
- Trial name
- NCT05296421
- Testing
- Biopsy, Therapeutic Conventional Surgery, Uniformly-labeled [13C]glucose
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Rutgers, The State University of New Jersey
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.